95.16
price down icon1.59%   -1.54
pre-market  プレマーケット:  95.39   0.23   +0.24%
loading
前日終値:
$96.70
開ける:
$96.52
24時間の取引高:
2.46M
Relative Volume:
1.15
時価総額:
$18.68B
収益:
$4.58B
当期純損益:
$870.87M
株価収益率:
21.63
EPS:
4.3988
ネットキャッシュフロー:
$945.58M
1週間 パフォーマンス:
-6.19%
1か月 パフォーマンス:
-10.21%
6か月 パフォーマンス:
+36.16%
1年 パフォーマンス:
+31.97%
1日の値動き範囲:
Value
$94.66
$97.98
1週間の範囲:
Value
$94.34
$103.68
52週間の値動き範囲:
Value
$53.56
$109.28

Incyte Corp Stock (INCY) Company Profile

Name
名前
Incyte Corp
Name
セクター
Healthcare (1131)
Name
電話
(302) 498-6700
Name
住所
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
職員
2,617
Name
Twitter
@Incyte
Name
次回の収益日
2025-02-10
Name
最新のSEC提出書
Name
INCY's Discussions on Twitter

INCY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INCY
Incyte Corp
95.16 18.98B 4.58B 870.87M 945.58M 4.3988
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
437.01 112.15B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
692.58 73.91B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
415.21 56.81B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
889.41 55.46B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
194.17 41.92B 447.02M -1.18B -906.14M -6.1812

Incyte Corp Stock (INCY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-03 アップグレード Guggenheim Neutral → Buy
2025-10-08 ダウングレード Oppenheimer Outperform → Perform
2025-08-06 アップグレード Wells Fargo Equal Weight → Overweight
2025-08-01 開始されました Barclays Overweight
2025-06-16 アップグレード Stifel Hold → Buy
2025-03-18 ダウングレード Guggenheim Buy → Neutral
2025-03-18 ダウングレード William Blair Outperform → Mkt Perform
2024-12-17 開始されました UBS Neutral
2024-10-29 アップグレード BofA Securities Neutral → Buy
2024-10-01 開始されました Wolfe Research Outperform
2024-09-18 ダウングレード Truist Buy → Hold
2024-07-02 ダウングレード BMO Capital Markets Market Perform → Underperform
2024-05-23 開始されました Deutsche Bank Hold
2024-04-23 開始されました Cantor Fitzgerald Neutral
2024-02-23 開始されました Jefferies Buy
2024-02-14 ダウングレード JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 アップグレード Leerink Partners Market Perform → Outperform
2023-12-04 アップグレード Guggenheim Neutral → Buy
2023-11-21 ダウングレード Goldman Buy → Neutral
2023-07-25 開始されました Citigroup Buy
2023-05-04 ダウングレード BofA Securities Buy → Neutral
2023-04-10 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-03-24 アップグレード SVB Securities Underperform → Market Perform
2023-01-31 開始されました Piper Sandler Overweight
2022-08-03 ダウングレード Evercore ISI Outperform → In-line
2022-08-03 ダウングレード Guggenheim Buy → Neutral
2022-07-28 開始されました Wells Fargo Equal Weight
2022-02-09 ダウングレード SVB Leerink Mkt Perform → Underperform
2022-01-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2021-11-19 開始されました BMO Capital Markets Market Perform
2021-07-20 アップグレード The Benchmark Company Hold → Buy
2021-02-10 ダウングレード SVB Leerink Mkt Perform → Underperform
2021-01-07 開始されました Truist Buy
2021-01-04 アップグレード Guggenheim Neutral → Buy
2020-06-16 開始されました The Benchmark Company Hold
2020-05-06 ダウングレード JP Morgan Overweight → Neutral
2020-04-29 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-04-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-24 再開されました William Blair Outperform
2020-03-13 アップグレード BofA/Merrill Neutral → Buy
2020-02-04 再開されました BofA/Merrill Neutral
2020-01-03 繰り返されました BMO Capital Markets Market Perform
2020-01-03 ダウングレード Mizuho Buy → Neutral
2020-01-02 ダウングレード Guggenheim Buy → Neutral
2019-10-03 開始されました Mizuho Buy
2019-09-12 開始されました BMO Capital Markets Market Perform
2019-09-05 アップグレード JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 再開されました Morgan Stanley Equal-Weight
2019-09-05 アップグレード Oppenheimer Perform → Outperform
2019-05-21 開始されました Credit Suisse Neutral
2019-05-03 ダウングレード Barclays Overweight → Equal Weight
2019-04-11 開始されました Stifel Hold
2019-04-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-01-24 アップグレード William Blair Mkt Perform → Outperform
すべてを表示

Incyte Corp (INCY) 最新ニュース

pulisher
Dec 09, 2025

Incyte releases data that shows promise in treating rare blood disease - Delaware Business Now

Dec 09, 2025
pulisher
Dec 09, 2025

Sun Pharma Claims New Pill Distinct From Incyte's Hit Drug - Law360

Dec 09, 2025
pulisher
Dec 09, 2025

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia - BioSpace

Dec 09, 2025
pulisher
Dec 09, 2025

Incyte stock holds Market Perform rating at Citizens on CALR therapy lead - Investing.com

Dec 09, 2025
pulisher
Dec 09, 2025

Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap? - Yahoo Finance

Dec 09, 2025
pulisher
Dec 08, 2025

Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? - Yahoo Finance

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte (INCY) Reports Promising Phase 1 Results for INCA033989 i - GuruFocus

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte’s experimental drug shows strong response in blood disorder By Investing.com - Investing.com Canada

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte’s experimental drug shows strong response in blood disorder - Investing.com

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte presents data showing 90% response rate for blood cancer drug - StreetInsider

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch

Dec 08, 2025
pulisher
Dec 08, 2025

Institution Moves: Why Incyte Corporation ICY stock stays undervaluedWatch List & Short-Term Trading Alerts - BỘ NỘI VỤ

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte (NASDAQ:INCY) Trading Down 6.6%Should You Sell? - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte (INCY) Maintained as Equal-Weight by Morgan Stanley with Raised Price Target | INCY Stock News - GuruFocus

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia - marketscreener.com

Dec 08, 2025
pulisher
Dec 08, 2025

INCY: Wells Fargo Raises Price Target to $116 | INCY Stock News - GuruFocus

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status - Yahoo Finance

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte (INCY) Stock Receives Upgraded Rating and Price Target from Mizuho | INCY Stock News - GuruFocus

Dec 08, 2025
pulisher
Dec 08, 2025

What's Going On With Incyte Stock Monday?Incyte (NASDAQ:INCY) - Benzinga

Dec 08, 2025
pulisher
Dec 08, 2025

Leerink Partners Adjusts Incyte Price Target to $128 From $103, Maintains Outperform Rating - marketscreener.com

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte stock price target raised to $128 by Leerink on mCALR data - Investing.com

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte Corporation $INCY Shares Purchased by American Century Companies Inc. - MarketBeat

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte Says Rare Blood Cancer Therapy Receives FDA Breakthrough Designation - marketscreener.com

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte Names Veteran Biopharma Attorney as New General Counsel - MyChesCo

Dec 08, 2025
pulisher
Dec 08, 2025

Wells Fargo Adjusts Price Target on Incyte to $116 From $97, Maintains Overweight Rating - marketscreener.com

Dec 08, 2025
pulisher
Dec 08, 2025

Mizuho upgrades Incyte stock rating to Outperform on promising ASH data - Investing.com

Dec 08, 2025
pulisher
Dec 08, 2025

Incyte stock price target raised by BofA to $118 on promising blood disorder data - Investing.com

Dec 08, 2025
pulisher
Dec 08, 2025

Mizuho Upgrades Incyte to Outperform From Neutral, Adjusts Price Target to $121 From $90 - marketscreener.com

Dec 08, 2025
pulisher
Dec 08, 2025

First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY - MarketBeat

Dec 08, 2025
pulisher
Dec 07, 2025

Transcript : Incyte CorporationSpecial Call - marketscreener.com

Dec 07, 2025
pulisher
Dec 07, 2025

Incyte (INCY) Secures FDA Breakthrough Therapy Designation for I - GuruFocus

Dec 07, 2025
pulisher
Dec 07, 2025

Incyte (INCY) Reveals Promising Phase 1 Results for INCA033989 i - GuruFocus

Dec 07, 2025
pulisher
Dec 07, 2025

Incyte (INCY) Receives FDA Breakthrough Therapy Designation for INCA033989 - GuruFocus

Dec 07, 2025
pulisher
Dec 07, 2025

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 - Yahoo Finance

Dec 07, 2025
pulisher
Dec 07, 2025

18,946 Shares in Incyte Corporation $INCY Bought by 1832 Asset Management L.P. - MarketBeat

Dec 07, 2025
pulisher
Dec 06, 2025

Incyte: Buy At This Inflection Point (NASDAQ:INCY) - Seeking Alpha

Dec 06, 2025
pulisher
Dec 06, 2025

Lido Advisors LLC Buys Shares of 13,529 Incyte Corporation $INCY - MarketBeat

Dec 06, 2025
pulisher
Dec 06, 2025

Marshall Wace LLP Takes Position in Incyte Corporation $INCY - MarketBeat

Dec 06, 2025
pulisher
Dec 06, 2025

Incyte Corporation $INCY Shares Bought by Fisher Asset Management LLC - MarketBeat

Dec 06, 2025
pulisher
Dec 05, 2025

Dodge & Cox Sells 269,147 Shares of Incyte Corporation $INCY - MarketBeat

Dec 05, 2025
pulisher
Dec 04, 2025

Insider Selling: Incyte (NASDAQ:INCY) EVP Sells 20,105 Shares of Stock - MarketBeat

Dec 04, 2025
pulisher
Dec 04, 2025

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 3, 2025 - BioSpace

Dec 04, 2025
pulisher
Dec 04, 2025

Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Dec 04, 2025
pulisher
Dec 03, 2025

VP Stein Sells 22,664 ($2.3M) Of Incyte Corp [INCY] - TradingView

Dec 03, 2025
pulisher
Dec 03, 2025

Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo - Yahoo Finance

Dec 03, 2025
pulisher
Dec 03, 2025

Myeloproliferative Disorder Treatment Market Size Report 2032 - openPR.com

Dec 03, 2025
pulisher
Dec 03, 2025

Mackenzie Financial Corp Has $24.67 Million Stock Position in Incyte Corporation $INCY - MarketBeat

Dec 03, 2025
pulisher
Dec 03, 2025

Korea Investment CORP Decreases Stake in Incyte Corporation $INCY - MarketBeat

Dec 03, 2025
pulisher
Dec 02, 2025

Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding - Business Wire

Dec 02, 2025
pulisher
Dec 02, 2025

Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel - BioSpace

Dec 02, 2025
pulisher
Dec 02, 2025

Hsbc Holdings PLC Cuts Position in Incyte Corporation $INCY - MarketBeat

Dec 02, 2025

Incyte Corp (INCY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$30.93
price down icon 3.16%
$38.09
price down icon 1.50%
$95.85
price down icon 1.47%
biotechnology ONC
$318.69
price down icon 2.39%
$194.17
price down icon 1.21%
大文字化:     |  ボリューム (24 時間):